Becton DickinsonBDXEarnings & Financial Report
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
BDX Q1 2026 Key Financial Metrics
売上高
$5.3B
粗利益
$2.4B
営業利益
$552.0M
純利益
$382.0M
粗利益率
45.9%
営業利益率
10.5%
純利益率
7.3%
前年比成長
-0.4%
EPS
$1.34
資金フロー
Becton Dickinson Q1 2026 Financial Summary
Becton Dickinson reported revenue of $5.3B for Q1 2026, with a net profit of $382.0M (7.3% margin). Cost of goods sold was $2.8B, operating expenses totaled $1.9B.
Key Financial Metrics
| Total Revenue | $5.3B |
|---|---|
| Net Profit | $382.0M |
| Gross Margin | 45.9% |
| Operating Margin | 10.5% |
| Report Period | Q1 2026 |
Becton Dickinson Annual Revenue by Year
Becton Dickinson annual revenue history includes year-by-year totals (for example, 2025 revenue was $21.5B).
| Year | Annual Revenue |
|---|---|
| 2025 | $21.5B |
| 2024 | $20.2B |
| 2023 | $19.3B |
| 2022 | $18.9B |
損益計算書
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $4.99B | $4.99B | $5.17B | $5.27B | $5.51B | $5.51B | $5.25B | $5.25B |
| 前年比成長 | 2.3% | 2.3% | 9.8% | 4.5% | 10.4% | 10.4% | 1.6% | -0.4% |
貸借対照表
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $55.58B | $57.29B | $54.66B | $54.47B | $54.90B | $55.33B | $54.84B | $54.84B |
| 総負債 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 株主資本 | $25.87B | $25.89B | $25.20B | $25.24B | $25.47B | $25.39B | $25.28B | $25.28B |
キャッシュフロー
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $1.30B | $1.18B | $693.0M | $164.0M | $1.22B | $1.35B | $657.0M | $657.0M |
Other Health Care Companies
ABT
Abbott Laboratories
売上高
$11.4B
純利益
$1.6B
BAX
Baxter International
売上高
$3.0B
純利益
$-1.1B
BSX
Boston Scientific
売上高
$5.3B
純利益
$670.0M
DXCM
Dexcom
売上高
$1.3B
純利益
$267.3M
EW
Edwards Lifesciences
売上高
$1.6B
純利益
$291.1M
GEHC
GE HealthCare
売上高
$5.7B
純利益
$588.0M
HOLX
Hologic
売上高
$1.0B
純利益
$179.1M
IDXX
Idexx Laboratories
売上高
$1.1B
純利益
$274.6M
PODD
Insulet Corporation
売上高
$783.7M
純利益
$101.6M
ISRG
Intuitive Surgical
売上高
$2.9B
純利益
$794.8M